The SELECT trial demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events (heart attack, stroke, and cardiovascular death) by 20% in adults with overweight or obesity and established heart disease (Lincoff et al., SELECT trial, New England Journal of Medicine , 2023)
First, rates are highest during dose escalation and usually improve with time on a steady dose
Patients need to carefully research options to make sure theyre getting high-quality care
View Article This article is for informational purposes only and does not constitute medical advice
Obesity (Silver Spring, Md) 2014;22(1):513
When you inject semaglutide, it binds exclusively to GLP-1 receptors throughout your body